Vabysmo
Generic: Faricimab
Daily Dose:
Course Duration:
Cheaper & Alternative Brands (6 mg/0.05 ml)
Same active generic (Faricimab), same form (IV Injection), exact same strength (6 mg/0.05 ml)No other brands currently registered with this exact active generic and dosage form.
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Vabysmo is a bispecific angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of:
Neovascular (wet) age-related macular degeneration (nAMD)
Diabetic macular edema (DME)
Macular edema secondary to retinal vein occlusion (RVO)
Dosage & Administration
General
: For intravitreal injection only. VABYSMO must be administered by a qualified physician experienced in intravitreal injections. Each vial should only be used for the treatment of a single eye.
Neovascular (wet) age-related macular degeneration (nAMD)
: The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses, followed by 6 mg (0.05 mL) via intravitreal injection at a dosing interval of up to every 16 weeks (4 months). Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion.
Diabetic macular edema (DME)
: The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses, followed by 6 mg (0.05 mL) via intravitreal injection at intervals of up to every 16 weeks (4 months). Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion.
Macular edema secondary to retinal vein occlusion (RVO)
: The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly). Monitoring between the dosing visits should be scheduled based on the patient’s status and at the physician’s discretion.
Contraindications
Faricimab is contraindicated in patients with ocular or periocular infections.
Faricimab is contraindicated in patients with active intraocular inflammation.
Faricimab is contraindicated in patients with known hypersensitivity to faricimab or any of the excipients. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.
Pharmacology & Mechanism of Action
Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralization of both Ang-2 and vascular endothelial growth factor A (VEGF-A). Ang-2 causes vascular instability by promoting endothelial destabilization, pericyte loss, and pathological angiogenesis, thus potentiating vascular leakage and inflammation. It also sensitizes blood vessels to the activity of VEGF-A resulting in further vascular destabilization. Ang-2 and VEGF-A synergistically increase vascular permeability and stimulate neovascularization. By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability.